Associated Disease Details
| Disease ID: | I09 |
| DO ID: | 104 |
| Disease Name: | Bacterial infectious disease |
| Definition: | A disease by infectious agent that results_in infection, has_material_basis_in Bacteria. http://en.wikipedia.org/wiki/Pathogenic_bacteria |
| Synonyms: | Bartonella Infections; Chlamydia Infections; Escherichia coli Infections; HIV Infections; Rickettsia Infections; Chlamydia trachomatis infection of genital structure; GONOCOCCAL INFECTION DISSEMINATED; Infection of skin AND/OR subcutaneous tissue; Lower respiratory tract infection; Pulmonary Mycobacterium avium complex infection; Staphylococcus aureus infection; Streptococcus pyogenes infection; Chlamydial pelvic inflammatory disease; Chlamydial pneumonia; Cholera; Urinary tract infection; Trachoma; Tuberculosis |
| Class: | disease by infectious agent |
| Related Drugs: | Amoxicillin; Azithromycin; CLA; Doxycycline; Raltegravir; TAF |
| Mechanism: | It has become evident that patients suffering from NAFLD might be at higher risk of developing various infections. The proposed mechanism for this association includes links through hyperglycemia, insulin resistance, alterations in innate immunity, obesity, and vitamin D deficiency. Additionally, a risk independent of these factors mediated by alterations in gut microbiota might contribute to a higher burden of infections in these individuals. |
| Reference (PMIDs): | 33977096 |
| Candidate ID | Source ID | Source Type | Compound Type | Candidate Name | Inclusion Criteria | |
|---|---|---|---|---|---|---|
| R0008 | DB00022 | approved | biotech | Peginterferon alfa-2b | Therapeutic strategy associated | Details |
| R0017 | DB00051 | approved; experimental | biotech | Adalimumab | Therapeutic strategy associated | Details |
| R0042 | DB00131 | approved; investigational; nutraceutical | small molecule | Adenosine phosphate | Target associated | Details |
| R0073 | DB00199 | approved; investigational; vet_approved | small molecule | Erythromycin | Indication associated | Details |
| R0205 | DB00591 | approved; investigational; vet_approved | small molecule | Fluocinolone acetonide | Therapeutic strategy associated | Details |
| R0225 | DB00635 | approved; vet_approved | small molecule | Prednisone | Therapeutic strategy associated | Details |
| R0460 | DB01234 | approved; investigational; vet_approved | small molecule | Dexamethasone | Therapeutic strategy associated | Details |
| R0488 | DB01319 | approved | small molecule | Fosamprenavir | Therapeutic strategy associated | Details |
| R0726 | DB05186 | investigational | small molecule | SQ-109 | Indication associated | Details |
| R0739 | DB05212 | investigational | small molecule | HE3286 | Therapeutic strategy associated | Details |
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A00048 | 35243281 | JHEP Rep | Artificial intelligence in liver diseases: Improving diagnostics, prognostics and response prediction. | Details |
| A00520 | 35054428 | Life (Basel) | The Possible Association of Non-Alcoholic Fatty Liver Disease with Acute Cholangitis: A Retrospective Multicenter Cohort Study. | Details |
| A00893 | 34938631 | Cureus | Glycogenic Hepatopathy as the Etiology of Abnormal Liver Chemistries in an Uncontrolled Type I Diabetic Patient. | Details |
| A01118 | 34863942 | Mol Metab | The metabolic syndrome, thiazolidinediones, and implications for intersection of chronic and inflammatory disease. | Details |
| A01258 | 34813249 | Arch Argent Pediatr | [Obesity-fatty liver: the role of the pediatrician]. | Details |
| A01323 | 34787756 | Biochem Genet | Identification of Key Pathways and Genes in SARS-CoV-2 Infecting Human Intestines by Bioinformatics Analysis. | Details |
| A01527 | 34707687 | Therap Adv Gastroenterol | Safety of anti-TNF agents in patients with compensated cirrhosis: a case-control study. | Details |
| A01592 | 34684371 | Nutrients | Advanced Glycation End-Products in Common Non-Infectious Liver Diseases: Systematic Review and Meta-Analysis. | Details |
| A01665 | 34662732 | Environ Toxicol Pharmacol | Deciphering the toxicological role of Porphyromonas gingivalis derived endotoxins in liver diseases. | Details |
| A01797 | 34611524 | J Hepatocell Carcinoma | An Analysis of Individual and Contextual-Level Disparities in Screening, Treatment, and Outcomes for Hepatocellular Carcinoma. | Details |
| A01881 | 34574647 | Int J Environ Res Public Health | Bone Mineral Density in Congenital Generalized Lipodystrophy: The Role of Bone Marrow Tissue, Adipokines, and Insulin Resistance. | Details |
| A01928 | 34559251 | Arch Toxicol | Aryl hydrocarbon receptor (AHR) functions in infectious and sterile inflammation and NAD+-dependent metabolic adaptation. | Details |
| A02058 | 34517451 | Zhonghua Gan Zang Bing Za Zhi | [Emphasizing the mutual effects of metabolic-associated fatty liver disease with infectious disease]. | Details |
| A02097 | 34508669 | Lancet Gastroenterol Hepatol | Health-care provision and policy for non-alcoholic fatty liver disease in sub-Saharan Africa. | Details |
| A02415 | 34381984 | JHEP Rep | The role of cGAS-STING signalling in liver diseases. | Details |
| A02608 | 34311133 | Clin Res Hepatol Gastroenterol | How will NAFLD change the liver transplant landscape in the 2020s? | Details |
| A02884 | 34205986 | Med Sci (Basel) | Hepatocrinology. | Details |
| A03005 | 34168043 | BMJ Open Gastroenterol | Exercising in the COVID-19 era: implications in non-alcoholic fatty liver disease (NAFLD). | Details |
| A03334 | 34040322 | World J Gastroenterol | Individualized treatment options for patients with non-cirrhotic and cirrhotic liver disease. | Details |
| A03363 | 34027561 | Arch Toxicol | Infections at the nexus of metabolic-associated fatty liver disease. | Details |